Related content

Vaccination with p53-peptide–pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study

By Svane Inge   Pedersen Anders   Johnsen Hans   Nielsen Dorte   Kamby Claus   Gaarsdal Eva   Nikolajsen Kirsten   Buus Søren   Claesson Mogens  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 7, 2004-07 ,pp. : 633-641

Springer Publishing Company

Access to resources Recommend Favorite

High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer

By Met Özcan   Balslev Eva   Flyger Henrik   Svane Inge  

Breast Cancer Research and Treatment, Vol. 125, Iss. 2, 2011-01 ,pp. : 395-406

Springer Publishing Company

Access to resources Recommend Favorite

Downregulation of ubiquitin E3 ligase TNF receptor-associated factor 7 leads to stabilization of p53 in breast cancer

By              

Oncology Reports, Vol. 29, Iss. 1, 2013-01 ,pp. : 283-287

Spandidos Publications

Access to resources Recommend Favorite

Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide–pulsed dendritic cells

By Matsuda Kenji   Tsunoda Takuya   Tanaka Hajime   Umano Yasukazu   Tanimura Hiroshi   Nukaya Ikuei   Takesako Kazutoh   Yamaue Hiroki  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 7, 2004-07 ,pp. : 609-616

Springer Publishing Company

Access to resources Recommend Favorite

Role of p53β in the inhibition of proliferation of gastric cancer cells expressing wild-type or mutated p53

By                

Molecular Medicine Reports, Vol. 12, Iss. 1, 2015-01 ,pp. : 691-695

Spandidos Publications

Access to resources Recommend Favorite